Why McKesson (MCK) is back on investors’ radar

McKesson (MCK) has attracted fresh attention after reporting strong third quarter results, with double digit revenue growth and earnings ahead of Wall Street forecasts, followed by a 16.5% jump in the share price.

The post earnings jump has also shifted the bigger picture for McKesson, with a 15.5% 1 month share price return adding to an 8.9% 3 month gain and a very large 5 year total shareholder return of 475.81%. Alongside upbeat earnings, fresh analyst optimism and a shareholder investigation into potential dilution from the 2013 Stock Plan are both influencing how investors think about McKesson’s future risk and reward profile.

If strong execution in healthcare is on your radar, it could be a good moment to see what else is moving and check out 27 healthcare AI stocks as a fresh set of ideas.

With McKesson trading at $947.48 against an average analyst price target of $980.40 and an estimated intrinsic discount of about 36%, the question becomes whether there is still value on the table or the market is already pricing in future growth.

Most Popular Narrative: 1.9% Undervalued

McKesson’s most followed narrative points to a fair value of about $966, slightly above the last close at $947.48. This keeps the focus firmly on what is baked into those future cash flow assumptions rather than the recent share price spike.

Investments in digitization, automation, and advanced analytics across distribution centers and logistics (e.g., automated picking systems, AI, robotics) are enhancing operational efficiency, driving measurable reductions in operating expenses and supporting long-term net margin improvement.

Curious what kind of revenue runway and margin lift are needed to support that fair value, and what future earnings multiple ties it all together, without relying on aggressive top line assumptions or outlier profit forecasts?

Result: Fair Value of $966 (UNDERVALUED)

However, that fair value story still leans on assumptions that could be tested if drug pricing pressure tightens margins or if industry consolidation squeezes McKesson’s wholesale role.

Another Way To Look At McKesson’s Price Tag

While the narrative and intrinsic value work point to McKesson looking undervalued, the simple P/E check tells a tighter story. At 26.7x earnings, the shares trade above the US Healthcare average of 23.9x but below peers at 29.1x and the fair ratio of 35.5x. This raises the question of whether the stock is trading at a premium that still leaves some cushion, or at a price that already assumes a lot going right.

Next Steps

With mixed signals on value, risk, and reward, do you want to rely on one narrative or weigh the evidence yourself and move early on your view? To see how the trade off between upside and concern really looks, take a close look at the 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If this McKesson story has sharpened your focus, do not stop here. Use the screener to hunt for other opportunities that fit your style.

• Zero in on value by checking companies that look mispriced on fundamentals with our 54 high quality undervalued stocks pulled from the screener.
• Strengthen your watchlist by focusing on financially robust names through the solid balance sheet and fundamentals stocks screener (43 results) identified by the screener.
• Get ahead of the crowd by reviewing a screener containing 23 high quality undiscovered gems surfaced by the screener before attention piles in.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.